Americans deserve medicines that are affordable. They also deserve medicines that are safe, FDA-approved, honestly marketed and developed in a system capable of producing tomorrow’s cures.
Federal regulators are turning up the heat on sellers of copycat weight-loss drugs. Earlier this summer, the Food and Drug Administration sent warning letters to dozens of companies marketing compounded GLP-1s over misleading advertising.
That action is more than welcome. The growing trade in compounded GLP-1s continues to expose patients to serious health risks. If left unchecked, it could have devastating effects on the future of medical innovation.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
The sneaky, unregulated dangers of copycat GLP-1 drugs
Sally C. Pipes
Americans deserve medicines that are affordable. They also deserve medicines that are safe, FDA-approved, honestly marketed and developed in a system capable of producing tomorrow’s cures.
Federal regulators are turning up the heat on sellers of copycat weight-loss drugs. Earlier this summer, the Food and Drug Administration sent warning letters to dozens of companies marketing compounded GLP-1s over misleading advertising.
That action is more than welcome. The growing trade in compounded GLP-1s continues to expose patients to serious health risks. If left unchecked, it could have devastating effects on the future of medical innovation.
Read the entire op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.